Compare WD & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | PLSE |
|---|---|---|
| Founded | 1937 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2010 | 2015 |
| Metric | WD | PLSE |
|---|---|---|
| Price | $50.34 | $26.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $76.00 | $22.00 |
| AVG Volume (30 Days) | 315.1K | ★ 358.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,234,306,000.00 | N/A |
| Revenue This Year | $20.60 | $840.00 |
| Revenue Next Year | $7.79 | $287.54 |
| P/E Ratio | $108.65 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $42.12 | $12.56 |
| 52 Week High | $90.00 | $31.00 |
| Indicator | WD | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 49.42 |
| Support Level | $47.77 | $23.94 |
| Resistance Level | $56.01 | $27.82 |
| Average True Range (ATR) | 1.83 | 1.80 |
| MACD | -0.46 | -0.17 |
| Stochastic Oscillator | 19.96 | 23.28 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.